Observational studyMovement disorders clinical practice2026
Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study.
Observational study in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Characteristics and Hospitalization Details of Patients with Advanced Parkinson's Disease Receiving Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa: Real-World First-Year Descriptive Study from Japan.Neurology and therapy · 2026Article
- Neuropsychiatric Adverse Events Associated With Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Clinical Practice: A Multicenter Study.European journal of neurology · 2026Observational
- Sex Differences in the Treatment of People with Parkinson's Disease with a Device-Aided Therapy: A Prospective Real-World Study.Medical sciences (Basel, Switzerland) · 2026Observational
- Outcome of People with Parkinson's Disease Treated with Levodopa-Entacapone-Carbidopa Intestinal Gel Who Failed Previous Subcutaneous Foslevodopa/Foscarbidopa.Brain sciences · 2026Article
- Nationwide analysis of real-world access to and use of device-aided therapies in Parkinson's disease: insights from the French National Healthcare Data System (2015-2021).BMJ neurology open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
BACKGROUND AND
objectiveNew device-aided therapies (DATs) have emerged to treat people with Parkinson's disease (PwP). Our aim was to know which DATs were indicated by the neurologist and to compare the characteristics of the patients treated under real clinical practice in Spain in the year 2024. PATIENTS AND
methodsData collected in the DATs-PD GETM Spanish Registry were used (REDCap). This is a descriptive, observational, prospective, multicenter, clinical registry with progressive inclusion of PwP treated with a DAT in daily clinical practice conditions in more than 40 centers from Spain for 10 years. For this proposal, only data from visit V1 (indication of DAT) were analyzed, but no follow-up data. All patients with information on DAT received until 31/DEC/2024 were included.
resultsA total of 313 PD patients (66.7 ± 9.6 years old at V2; 61.7% males) were treated with a DAT. The most frequent DAT was subcutaneous foslevodopa/foscarbidopa (fLD/fCD) (47%) followed by deep brain stimulation (DBS) (20.1%) and continuous subcutaneous apomorphine infusion (CSAI) (19.8%). Up to 23.6% had received at least one previous DAT and 47% an on-demand therapy. Differences in age, time with fluctuations and other aspects (motor status, quality of life or activities of daily living among others) were observed between different DAT groups. Specifically, patients treated with DBS were younger and had less advanced disease, whereas those who received LECIG were the most affected.
conclusionSubcutaneous therapies and DBS were the most frequent DATs (86.9%) implemented in Spain in 2024. Profile differences were detected between DAT types.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.